An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer.
An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer.
复制标题
基于免疫细胞浸润的免疫评分模型可预测乳腺癌的预后和化疗效果。
作者：
Sui S;An X;Xu C;Li Z;Hua Y;Huang G;Sui S;Long Q;Sui Y;Xiong Y;Ntim M;Guo W;Chen M;Deng W;Xiao X;Li M
背景资料：免疫细胞具有重要的辅助功能并影响癌症的临床结果，高免疫浸润与乳腺癌（BC）的临床结果改善和治疗反应更好相关。然而，迄今为止的研究尚未充分考虑肿瘤中的肿瘤浸润免疫细胞（TIIC）景观。本研究调查了基于TIIC的潜在生物标志物，以改善BC的预后和治疗效果。结果如下：我们招募了5112例患者进行分析，并通过估计RNA转录物的相对子集（CIBERSORT）（一种新的计算算法）进行细胞类型鉴定，以量化原发性BC中的22个TIIC。单因素考克斯回归分析结果显示，12种免疫细胞与BC患者的总生存期（OS）显著相关。此外，应用最小绝对收缩和选择算子（LASSO）和多变量考克斯回归分析来构建基于六种潜在生物标志物的免疫预后模型。通过将患者分为低风险组和高风险组，在训练队列中发现OS的显著差异，20年生存率分别为42.6%和26.3%。将类似的方案应用于验证和测试队列，我们发现无论BC的分子亚型如何，高风险组的OS均显著短于低风险组。使用免疫评分模型预测BC患者对化疗的影响，低风险组的生存优势在接受化疗的患者中是明显的，无论化疗方案如何。在评估诺模图的预测价值时，决策曲线显示出比标准肿瘤淋巴结转移（TNM）分期系统更好的预测准确性。结论：基于免疫细胞浸润的免疫评分模型可以有效地用于预测BC患者的预后以及化疗效果。
Background: Immune cells have essential auxiliary functions and influence clinical outcomes in cancer, with high immune infiltration being associated with improved clinical outcomes and better response to treatment in breast cancer (BC). However, studies to date have not fully considered the tumor-infiltrating immune cell (TIIC) landscape in tumors. This study investigated potential biomarkers based on TIICs to improve prognosis and treatment effect in BC. Results: We enrolled 5112 patients for analysis and used cell type identification by estimating relative subsets of RNA transcripts (CIBERSORT), a new computational algorithm, to quantify 22 TIICs in primary BC. From the results of univariate Cox regression, 12 immune cells were determined to be significantly related to the overall survival (OS) of BC patients. Furthermore, least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analyses were applied to construct an immune prognostic model based on six potential biomarkers. By dividing patients into low- and high-risk groups, a significant distinction in OS was found in the training cohort, with 20-year survival rates of 42.6% and 26.3%, respectively. Applying a similar protocol to validation and test cohorts, we found that OS was significantly shorter in the high-risk group than in the low-risk group, regardless of the molecular subtype of BC. Using the immune score model to predict the effect of BC patients to chemotherapy, the survival advantage for the low-risk group was evident among those who received chemotherapy, regardless of the chemotherapy regimen. In evaluating the predictive value of the nomogram, a decision curve showed better predictive accuracy than the standard tumor-node-metastasis (TNM) staging system. Conclusion: The immune cell infiltration-based immune score model can be effectively and efficiently used to predict the prognosis of BC patients as well as the effect of chemotherapy.
登录
查看更多内容
影响因子：
64.5
作者：
Fan X;Rudensky AY
通讯作者：
Rudensky AY
影响因子：
20.4
作者：
He, Yayi;Yu, Hui;Hirsch, Fred R.
通讯作者：
Hirsch, Fred R.
影响因子：
45.3
作者：
Adams, Sylvia;Gray, Robert J.;Badve, Sunil S.
通讯作者：
Badve, Sunil S.
影响因子：
5.8
作者：
Diederichsen, ACP;Hjelmborg, JV;Fenger, C
通讯作者：
Fenger, C
影响因子：
--
作者：
Baier, PK;Wimmenauer, S;Farthmann, EH
通讯作者：
Farthmann, EH